Alx Oncology Holdings (ALXO) Other Operating Expenses (2019 - 2025)

Alx Oncology Holdings (ALXO) reported Other Operating Expenses of $3.2 million for Q2 2025, up 562.84% sequentially from $479000.0 in Q2 2020.

Alx Oncology Holdings (ALXO) Other Operating Expenses (2019 - 2025) Analysis & Trends

Alx Oncology Holdings (ALXO) has 3 years of Other Operating Expenses data on file, last reported at $3.2 million in Q2 2025.

For the quarter ending Q2 2025, Other Operating Expenses changed N/A year-over-year to $3.2 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 million (changed N/A YoY), and the FY2025 full-year result was $3.2 million, changed N/A from the prior year.
Other Operating Expenses advanced to $3.2 million in Q2 2025, from $479000.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $3.2 million in Q2 2025 to a low of $3.2 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Alx Oncology Holdings	211.24 Mn	211.24 Mn	-

Download Data